Waldencast reported Q4 2025 net revenue of USD 72.0 million, down 0.1%, and adjusted EBITDA of USD 6.6 million, down 41%. Q4 net loss was USD 33.51 million, driven mainly by financing costs related to the refinancing of credit facilities. For FY 2025, net revenue was USD 272.1 million, down 0.7%, and adjusted EBITDA was USD 16.1 million, down 60%, reflecting lower adjusted gross margin and investment tied to supply chain rationalization and 2026 launches including Obagi’s expansion into medical aesthetics. FY net loss was USD 248.06 million, primarily due to impairment charges on Obagi and Milk Makeup, depreciation and amortization, and financing costs including those incurred from the credit facility refinancing. Waldencast said it is not providing a 2026 outlook due to its ongoing strategic review, for which it has retained Lazard as financial adviser.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001840199-26-000020), on March 13, 2026, and is solely responsible for the information contained therein.
Comments